Methuselah Funds

What Methuselah Funds does

Methuselah Funds, LLC (M Fund) is a privately held venture capital fund established in 2016 as the dedicated investment arm of the Methuselah Foundation, a nonprofit organization that has operated in the longevity field for 16 years. The fund invests exclusively in biotechnology companies developing anti-aging and longevity therapies, deploying capital across seven structured intervention strategies: organ and bone regeneration (New Parts for People), cellular information integrity (Debug the Code), fascia and skin fortification (Rebuild the Walls), senescent cell removal (Get the Crud Out), stem cell and antibody replenishment (Restock the Shelves), circulatory system restoration (Restore the Rivers), and sensory/athletic rejuvenation (Lust for Life). The fund's stated mission is "making 90 the new 50 by 2030," and the entity explicitly prioritizes mission advancement over financial returns.

The fund's portfolio comprises approximately eight named ventures spanning senolytics (Oisín Biotechnologies, reported 80% reduction in senescent cells in cell culture), epigenetic reprogramming (Turn Bio), 3D bioprinting (Volumetric), cancer therapeutics (OncoSenX), Alzheimer's intervention (Leucadia Therapeutics), 3D tissue drug discovery (Viscient Biosciences), cryopreservation technology (X-Therma), and nerve damage therapeutics (WinSanTor). The fund is supported by an advisory board featuring prominent figures in the longevity field, including Aubrey de Grey (Co-Founder of SENS Research Foundation and Methuselah Foundation), Keith Murphy (Chairman and Co-founder of Organovo, former Amgen executive), and personnel with policy and institutional investment pedigree.

M Fund operates a relationship-driven, network-based go-to-market model and does not publicly solicit investors or distribute services. The fund provides investment advisory services exclusively to privately offered M Fund funds, targeting sophisticated investors and prospective portfolio companies through direct outreach. Revenue is derived from returns on equity investments in portfolio biotech companies, with the entity structured as a US LLC with founder David Gobel — who also founded the Methuselah Foundation — serving as CEO. This structure indicates significant founder control and tight nonprofit-investment vehicle alignment.

Name

Methuselah Funds

Legal name

Methuselah Funds, LLC

Website

https://methuselahfund.com

Company type

Private

Founded year

2016

Operating status

Operating

Short description

Methuselah Funds, LLC (M Fund) is a private venture capital fund and investment arm of the nonprofit Methuselah Foundation, established in 2016. It deploys capital into biotechnology companies developing anti-aging and longevity therapies across seven structured intervention strategies.

Ownership category

akta.pro rank

Product category

Venture Capital (Longevity & Anti-Aging Biotechnology)

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industry

Impact Investment & Development Investment Funds (BPADACAO)

Keywords

• Longevity venture capital
• Anti-aging biotechnology
• Life extension investing
• Biotech venture funding
• Mission-driven investing

Headquarters

HQ city

Springfield

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Revenue model

1. Venture Capital Fund Management: M Fund generates returns through equity investments in portfolio biotech companies. Success is measured by both financial return on investments and furthering the mission of extending healthy human lifespan, with mission being the stated priority.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Methuselah Funds, LLC (M Fund) is a venture capital fund that invests in anti-aging biotechnology companies pursuing interventions to extend healthy human lifespan. The fund deploys capital across seven structured strategies covering organ regeneration, cellular reprogramming, tissue repair, senolytics, stem cell therapy, circulatory restoration, and sensory/physical rejuvenation, targeting portfolio companies such as Leucadia Therapeutics, Oisín Biotechnologies, Turn Bio, OncoSenX, Volumetric, Viscient, X-Therma, and WinSanTor.

Product overview

Methuselah Funds, LLC (M Fund) is a single unified venture capital fund focused exclusively on longevity and anti-aging biotechnology investments. The fund's mission is making 90 the new 50 by 2030. It does not operate as a platform with modular products; rather, it deploys capital into portfolio companies pursuing various anti-aging strategies including new organ creation, cellular reprogramming, senescent cell removal, and regenerative medicine approaches. The fund stems from the Methuselah Foundation, which has operated in the longevity space for over 16 years.

Differentiator

Problem solved

Functional benefit

Products and services

• Methuselah Funds, LLC (M Fund) A privately offered venture capital fund providing investment advisory services exclusively to M Fund LPs; invests equity in anti-aging biotechnology companies spanning organ regeneration, cellular reprogramming, senolytics, stem cell therapy, circulatory restoration, and tissue/sensory rejuvenation. Targets sophisticated investors and longevity-focused biotech portfolio companies; does not solicit or make services available to the public.

Quantifiable outcome

• 80% reduction in senescent cells demonstrated by portfolio company Oisín Biotechnologies in cell culture
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and major.

• Methuselah FoundationcoreStrategic or Co-development PartnerM Fund's DNA stems from The Methuselah Foundation, which has been working during the last 16 years to extend the healthy human lifespan. The foundation provides M Fund with significant access to key players in the longevity space and a proven ability to help portfolio companies thrive. The relationship is foundational, with shared mission alignment around extending healthy human lifespan.
• SENS Research FoundationcoreStrategic or Co-development PartnerSENS Research Foundation is co-founded by Aubrey de Grey, who also co-founded Methuselah Foundation. The foundation is a key thought leader in the longevity field, with shared research interests in damage repair approaches to aging. Multiple advisors including Kevin Perrott are connected to both organizations.
• OrganovomajorStrategic or Co-development PartnerKeith Murphy, Executive Advisor to M Fund, is Chairman and Co-founder of Organovo. Viscient Biosciences was founded and staffed by former Organovo scientists. The relationship provides expertise in 3D tissue technology and bio-printing for regenerative medicine applications.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Methuselah Funds